Drug Trial Radar · NCT04770220
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
325
Actual
Start
May 19, 2021
Primary completion
May 29, 2024
Study completion Jul 29, 2024
Sponsor
- Lead sponsor
- Alzheon Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Feb 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.
Conditions
- Early Alzheimer's Disease
Interventions
Experimental: ALZ-801Drug
ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID
Placebo Comparator: PlaceboDrug
Placebo tablet BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Cognitive Efficacy Endpoint (ADAS-Cog13)Time frame: Baseline to Week 78
- Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)Time frame: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
Locations
95 sites in 9 countries. Site status is shown where the registry gives one.
Xenoscience
Phoenix, Arizona
CCT Research
Scottsdale, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
ATP Clinical Research
Costa Mesa, California
Tilda Research
Irvine, California
UCSD Shiley-Marcos Alzheimer's Disease Research Center
La Jolla, California
Torrance Clinical Research Institute
Lomita, California
Collaborative NeuroScience Network LLC
Long Beach, California
Stanford University
Palo Alto, California
SC3 Research Group
Pasadena, California
Sutter Health
Sacramento, California
JEM Research Institute, Headlands Site
Atlantis, Florida
Bradenton Research Center
Bradenton, Florida
Galiz Research
Hialeah, Florida
Alphab Global Research
Jupiter, Florida
Charter Research
Lady Lake, Florida
K2 Medical Research, LLC
Maitland, Florida
Miami Jewish Health
Miami, Florida
Y & L Advance Health Care, Inc /DBA Elite Clinical Research
Miami, Florida
Mount Sinai Medical Center
Miami Beach, Florida
Aqualane Clinical Research
Naples, Florida
Charter Research
Orlando, Florida
Headlands Research Orlando
Orlando, Florida
Advanced Research Consultants
Palm Beach Gardens, Florida
Quantum CNS Clinical Research
Pompano Beach, Florida
Progressive Medical Research
Port Orange, Florida
ALZ Research and Treatment Center (A.R.T.C.)
Stuart, Florida
ALZ Research and Treatment Center (A.R.T.C.)
Wellington, Florida
Premiere Research Institute
West Palm Beach, Florida
Columbus Memory Center
Columbus, Georgia
Sandhill Research, LLC
Decatur, Georgia
Fort Wayne Neurological Center
Fort Wayne, Indiana
Louisiana State University Health Sciences Center (LSUHSC)
Shreveport, Louisiana
Headlands Research Eastern MA
Plymouth, Massachusetts
WR-CRCN
Las Vegas, Nevada
Advanced Memory Research Center
Toms River, New Jersey
Neurological Associates of Albany
Albany, New York
NYU Alzheimer's Disease Research Center
New York, New York
Kline Institute for Psychiatric Research
Orangeburg, New York
University of Rochester Medical Center
Rochester, New York
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.